Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers M > Headlines for Melinta Therapeutics, Inc. > News item |
Melinta marks $1.45 million operating loss for February; revenue up
By Caroline Salls
Pittsburgh, March 31 – Melinta Therapeutics, Inc. reported a $1.45 million loss from operations for February on $7.41 million in total revenue, according to its monthly operating report filed Monday with the U.S. Bankruptcy Court for the District of Delaware.
In comparison, Melinta posted a $4.64 million loss from operations for the period of Dec. 27 through Jan. 31 on $3.28 million in total revenue.
The net loss for February was $7.81 million, narrowing from a $22.57 million net loss for the previous period.
In addition, the company listed $52.07 million in cash and cash equivalents as of Feb. 29, down from $55.99 million at the end of January.
Melinta is an antibiotics company based in New Haven, Conn. The company filed bankruptcy on Dec. 27 under Chapter 11 case number 19-12748.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.